ABSTRACT Background: Obesity is the most important risk factor for obstructive sleep apnea (OSA). Weight-reduction programs have been observed to represent effective treatment of overweight patients with OSA. However, it is not known whether beneficial changes remain after the end of the intervention. Objective: The aim of the study was to assess the long-term efficacy of a lifestyle intervention based on a healthy diet and physical activity in a randomized, controlled, 2-y postintervention follow-up in OSA patients. Design: Eighty-one consecutive overweight [body mass index (in kg/m 2 ): 28-40] adult patients with mild OSA were recruited. The intervention group completed a 1-y lifestyle modification regimen that included an early 12-wk weight-reduction program with a verylow-calorie diet. The control group received routine lifestyle counseling. During the second year, no dietary counseling was offered. Change in the apnea-hypopnea index (AHI) was the main objective outcome variable, and changes in symptoms were used as a subjective measurement. Results: A total of 71 patients completed the 2-y follow-up. The mean (6 SD) changes in diet and lifestyle with simultaneous weight reduction (27.3 6 6.5 kg) in the intervention group reflected sustained improvements in findings and symptoms of OSA. After 2 y, the reduction in the AHI was significantly greater in the intervention group (P = 0.049). The intervention lowered the risk of OSA at follow-up; the adjusted odds ratio for OSA was 0.35 (95% CI: 0.12-0.97; P = 0.045). Conclusions: Favorable changes achieved by a 1-y lifestyle intervention aimed at weight reduction with a healthy diet and physical activity were sustained in overweight patients with mild OSA after the termination of supervised lifestyle counseling. This trial was registered at clinicaltrials.gov as NCT00486746.
INTRODUCTION
Obesity is a major worldwide health burden that contributes to increased morbidity and mortality (1) . It is also the most important risk factor for obstructive sleep apnea (OSA) (2) . Furthermore, prevalent OSA, as such, has been found to have an independent association with cardiovascular diseases, type 2 diabetes, metabolic syndrome, deterioration in an individual's quality of life and working capacity, and increased mortality (3) (4) (5) (6) (7) . Even mild OSA is related to an increased activation of the inflammatory system and the risk of cardiovascular morbidity, although the risk is more frequently associated with more severe degrees of the disease (8, 9) . On the other hand, originally mild OSA can progress to moderate or severe OSA (10, 11) , predominantly because of weight gain (11) . In the first randomized study conducted, we showed that a lifestyle intervention lasting 1 y, which included an early weight-reduction program, was a feasible and effective treatment of overweight patients with mild OSA (12) . These findings were supported by another randomized study of obese OSA patients with type 2 diabetes (13) . Most importantly, although these data are encouraging and weight loss is recommended in all clinical guidelines, it is not known whether these favorable changes are sustained after termination of the program. It is a common belief that weight gain could be expected, resulting in a reexacerbation of OSA. This randomized study was originally conducted to determine the effects of changes in lifestyle with a weight-reduction program designed to prevent the progression of the disease or even cure it in the most prevalent subgroup of OSA (ie, overweight patients with mild OSA). The main objective of our 2-y follow-up was to assess postinterventional results of lifestyle intervention aimed at improving objective measurements and clinical symptoms. Our hypothesis was that a successful weight reduction with lifestyle intervention including a very-low-calorie diet (VLCD) followed by an intensive dietary counseling according to current recommendations, and physical activity would result in sustained improvements of mild OSA and reduced morbidities related to OSA.
SUBJECTS AND METHODS
This study was a randomized, clinical, 2-y follow-up trial with 2 groups of patients with mild OSA. The patients in the intervention group received a 1-y lifestyle intervention that included an initial weight-reduction program consisting of 12 wk of a VLCD. For the control group, only one general dietary and exercise counseling session was provided. The detailed design of the study was previously reported (12) . The study protocol was approved by the Research Ethics Committee of the Hospital District of Northern Savo, Kuopio, Finland. The patients were given both oral and written information about the trial protocol, and they provided written consent. The recruitment was planned to last for 2 y, and it started in October 2004 and ended in December 2006.
Subjects
The study was conducted at the Kuopio University Hospital, Finland. The study subjects were consecutively recruited from the patients referred to the outpatient clinics of Otorhinolaryngology and Respiratory Medicine of the Kuopio University Hospital because of a clinical suspicion of sleep disordered breathing. Patients were assigned to undergo nocturnal cardiorespiratory monitoring. Weight and height were checked, and the upper airway signs of the patients were evaluated. The inclusion criteria for the initial trial were 1) age 18-65 y, 2) body mass index (BMI; in kg/m 2 ) 28-40, and 3) an apnea-hypopnea index (AHI) of 5 to 15 events/h. The study flow chart is presented in Figure 1 . After they visited the study physicians and it was confirmed that the patients fulfilled the inclusion criteria, the subjects were allocated randomly by a study nurse into 2 study groups: lifestyle intervention group or control group. A block randomization, but no stratification, was used in the allocation of the participants. The primary outcome measure was the magnitude of the change in AHI over the follow-up. The secondary outcome measures were changes in symptoms related to OSA and metabolic variables. During the 2-y follow-up, 10 patients (5 from each group) dropped out of the study. Most of the dropouts (7/10) occurred before the 3-mo visit, and only one patient dropped out after the 1-y visit. There was no difference in compliance between groups, and most of the patients who dropped out had reasons not related to the treatment.
Intervention
The dietary intervention had several main goals, including the reduction of dietary fat to 30% of total energy; an increase in the intake of fruit, vegetables, poultry, fish, and lean meat; and the limitation of dairy fats, fatty meat, and desserts. The clinical nutritionist provided dietary and lifestyle counseling at each of the 14 visits, specifically focusing on eating behavior. During the intervention period, the rate of participation in these sessions varied from 70% to 80%, and actual compliance with the intervention was achieved in 83% (29/35) of the patients. Compliance with the program was based on achieving the lifestyle goals agreed on by the nutritionist and the individual patient at the beginning of the intervention. Body weight was measured at each visit, and the patients were asked about the lifestyle changes they had undertaken. A detailed implementation of the intervention procedure was previously reported (12) . The intervention was initiated with a 12-wk VLCD providing 600-800 kcal/d via Nutrilett (Nycomed Pharma, Oslo, Norway), Modifast (Novartis, Basel, Switzerland), Nutrifast (Leiras, Turku, Finland), or Naturdiet (Vitamex, Norrköping, Sweden), which was followed by advice on how to improve the daily diet according to the current dietary recommendations. The nutritionist provided face-to-face counseling individually tailored to each patient in the intervention group and also participated in the group sessions. In addition to dietary counseling, the subjects in the intervention group were advised to increase their overall level of daily physical activity and endurance exercise (such as walking, skiing, jogging, or swimming). The possible changes undertaken and the frequency of physical activity of the participants were self-reported at the follow-up. The subjects in the control group were given standard care consisting of general oral and written information about diet and exercise at the baseline and 3-and 12-mo visits by the study nurse and physician without any specific individualized advice. During the second year, no intervention or advice was offered to either of the study groups, and the study nurse checked regularly that the participants did not receive any co-intervention for OSA other than that specified in the study design. The results of all laboratory tests, blood pressure measurements, and electrocardiograms taken were checked by study physicians. It was decided that if any abnormal test results endangering the health of the participants were observed, the participants would be informed and referred for appropriate medical care.
Procedures and measurements
Nocturnal cardiorespiratory monitoring by Embletta (Embla, Broomfield, CO) at home was conducted in accordance with accepted guidelines for diagnosing OSA (14) . The recordings were manually evaluated blindly with respect to clinical status and group by the same trained physician. Apnea was defined as the cessation (.90%) of airflow for .10 s with oxygen desaturation for 4%. Hypopnea was defined as a reduction (.30%) of airflow for .10 s with oxygen desaturation for 4%. The AHI was defined as the number of apneas and hypopneas per hour, and mild OSA was defined as an AHI of 5 to 15 events/h (14) . The OSA was considered objectively cured when the AHI was , 5 events/h. The sleep recordings, as well as the anthropometric measurements, were included in this report for the entire follow-up period: baseline, 3-mo, 1-y, and 2-y visits.
Previously validated questionnaires were used to screen for the intensity of snoring [Snore Outcomes Survey (SOS)] and daytime sleepiness [Epworth Sleepiness Scale (ESS)] (15, 16) . The respondents were also asked whether their bedfellows had FIGURE 1. Study flow chart. AHI, apnea-hypopnea index (the number of apnea-hypopnea events with at least a 4% oxygen desaturation per hour); ENT, ear, nose, and throat; QoL, quality of life (= 15D; 21, 22) . Sleep questionnaires included the Snore Outcomes Survey, the Epworth Sleepiness Scale, and information about witnessed apneas; 326 (60%) of the 544 excluded patients were considered simple snorers (ie, snoring reported as the only symptom and an AHI , 5 in sleep recordings).
noticed breathing pauses during sleep, and they were subsequently classified as "witnessed apneas."
Blood samples for biochemical assays were collected from fasting patients (12 h). All the biochemical measurements were performed in the laboratory of Clinical Chemistry of Kuopio University Hospital. Serum cholesterol, HDL cholesterol, serum triglycerides, and plasma glucose were measured in fresh serum samples by using an automated analyzer system (Konelab 60 Analyzer; ThermoFisher Scientific, Waltham, MA), and serum insulin was measured by using a fluoroimmunoassay system (Wallac; Perkin-Elmer, Waltham, MA).
Statistical analysis
The mean values and SDs were used to describe the baseline characteristics of the 2 treatment groups. Fisher's exact test or t test was used to assess equality between the treatment groups. Changes in sleep recordings and anthropometric measures during the follow-up were calculated by subtracting the baseline measurement from the 2-y follow-up measurement, and the mean difference in change between the treatment groups was calculated. The statistical significance of differences in changes between the groups was assessed with t tests and additionally with analysis of covariance (ANCOVA). In the ANCOVA models, baseline differences in age, sex, BMI, and the baseline level of the respective variables were accounted for by including these variables as explanatory variables in the model. Age and BMI were included in the models as continuous variables and sex as a dichotomous variable. Recovery from OSA was analyzed with a logistic regression model, with adjustment for baseline differences in age, sex, BMI, and AHI between the groups. The differences in risk are reported as odds ratios with 95% CIs. All comparisons between the treatment groups were based on the intention-to-treat principle, and all analyses were based on the 71 subjects who completed the 2-y follow-up. The study sample size was set to achieve 90% power at a 5% significance level to detect a 25% lower prevalence of mild OSA at the 2-y follow-up in the intervention group than in the control group. This calculation was done under the assumption that there would be no improvement in mild OSA in the control group. Analyses were conducted with the statistics package Stata [Stata Statistical Software, release 9.2, 2005; StataCorp LP, College Station, TX].
RESULTS
The baseline characteristics of the patients are shown in Table  1 and Table 2 . A total of 81 patients were originally randomly assigned into the study. The patients were observed to have significant symptoms related to their disease (ie, habitual and intensive snoring), many of whom reported significant daytime sleepiness (ESS 10). Despite the randomization, the mean anthropometric measures were significantly higher in the intervention group than in the control group. Recorded average sleeping time was slightly longer in the control group, but it was also .6 h in the intervention group. Otherwise, no differences in 4 Witnessed apneas (n = 62); data missing from 9 patients.
the relevant baseline characteristics were observed between the treatment groups.
Follow-up data

Anthropometric characteristics
During the 2-y follow-up period, the mean change in weight was 27.3 kg (7.2% of the initial weight) in the intervention group and was 22.9 kg (3.1% of the initial weight) in the control group (P = 0.09). A marked difference was found in the 2-y change in all anthropometric measurements between the study groups, although significant improvements also took place in the control group (Table 3 ). In the intervention group, the prevalence of patients getting regular physical activity (ie, 30 min of exercise 3 times/wk) increased from 36% at the baseline to 61% at the 2-y follow-up.
Sleep recordings
Although the association between weight loss and reduction of AHI was strong during the entire 2-y period, the reduction in the AHI in the intervention group was sustained despite the slight increase in weight occurring from the 3-mo visit to the 2-y follow-up (Figure 2 ). At the 3-mo visit, the actual mean total AHI was 6.5 events/h in the intervention group and 7.9 events/h in the control group, (P = 0.181), and 57% (20/35) of patients in the intervention group and 33% (12/36) of patients in the control group were objectively cured (AHI , 5; P = 0.058, Fisher's exact test). At the 1-y visit, the actual mean total AHI was 6.0 in the intervention group and 9.3 in the control group, (P = 0.06), and 63% (22/35) of patients in the intervention group and 36% (13/36) of patients in the control group were objectively cured (P = 0.033). At the 2-y visit, the actual mean total AHI was 5.4 in the intervention group and 9.1 for the control group (P = 0.038), and the mild OSA had been objectively cured in 57% (20/35) of patients in the intervention group and in 31% (11/36) of patients in the control group (P = 0.032). Moreover, there was a statistically significant difference in the mean change in total AHI between the study groups at the 2-y follow-up (Table 3) . The baseline BMI did not have any effect on the effectiveness of the lifestyle intervention (P value for the BMI-randomization group interaction was 0.947 when the change in total AHI was analyzed). When the baseline differences in age, sex, BMI, and AHI between the groups were taken into account, the adjusted odds ratio for having mild OSA at the 2-y follow-up was 0.35 (95% CI: 0.12, 0.97; P = 0.045) for the comparison between the intervention and control groups. Over the 2-y follow-up period, the OSA deteriorated from mild to moderate in 3 patients in the lifestyle intervention group, all with unsuccessful weight reduction, and in 6 patients in the control group. There was a trend toward an improvement in other cardiorespiratory recordings; however, after adjustments, the differences were no longer statistically significant (Table 3) .
Sleep questionnaires
At the 2-y visit, the change in the SOS was significant in the intervention group (33.3 points) compared with control group (17.5 points; P = 0.008). The ESS decreased greatly in both the intervention group (22.3 points) and the control group (22.8 points), but the difference between groups was not significant. There was also a significant reduction in "witnessed apneas" in both the intervention group (totally vanished in 87% of the patients) and the control group (60%) ( Table 3) .
Association between OSA and weight reduction and physical activity
Changes in the AHI during the 2-y follow-up were strongly associated with the changes in body weight (Figure 3 ). In the entire study population, a weight reduction of 5 kg from the initial body weight was associated with a reduction in AHI of 2.1 units (95% CI: 0.5, 3.8). The changes in the AHI were 26, 25, 21, and 2 in the weight-change categories of , 215 kg, 215 to 25 kg, 25 to 0 kg, and .0 kg, respectively. Mild OSA was objectively cured in 75% (3/4) of patients in the weightchange group , 215 kg as compared with 67% (20/30), 22% (5/23), and 21% (3/14) in the weight-change groups 215 to 25 kg, 25 to 0 kg, and .0 kg, respectively. Although the reduction in AHI was more profound in patients with regular exercise (25.4 events/h) than in those with less active patients (24.3 events/h), this difference was not statistically significant.
Biochemical measurements and blood pressure
A significant decrease in the serum fasting insulin concentration occurred in the intervention group; however, the difference was not significant from the control group. The reduction in the insulin concentration and AHI tended to correlate with each other (r = 0.24, P = 0.056). In the entire study population, changes in insulin were 211, 24, and 2 mU/L in the weightchange categories , 215 kg, 215 to 25 kg, and . 25 kg, respectively (P , 0.008 for adjusted trend test). No significant changes in the other biochemical variables were observed between the groups. There was a significant reduction in mean systolic blood pressure in favor of the control group; however, antihypertensive medication had been terminated during the follow-up period in 7 of 18 patients belonging to the intervention group compared with only 2 of 14 patients in the control group (Table 3) .
Adverse events
No abnormalities in clinical variables requiring further action were observed during the 2-y follow-up period.
DISCUSSION
This study provides evidence that changes in diet according to the current recommendations and increased physical activity along with weight reduction can result in marked improvements in objective measurements and clinical symptoms of OSA in overweight patients, even 1-y after the discontinuation of the intervention. In the intervention group, a 40% reduction in the AHI was achieved from the baseline, and 3 of 5 patients were considered to have been cured (ie, they had an AHI , 5). In the control group, only a slight decrease in the mean AHI was observed; however, because of significant weight loss in some patients, 3 of every 10 patients were observed to have an AHI , 5. Overall, the lifestyle intervention reduced the risk of OSA by 65%, and a 50% decrease was found in the progression of the disease compared with the control group during the 2-y period. In conjunction with the improvement in AHI, significant improvements were also found in symptoms related to OSA.
The association between obesity and OSA seems to be bidirectional; obesity itself increases the risk of OSA, but, on the other hand, OSA may also predispose an individual to weight gain (17) . It has been postulated that obesity leads to a narrowing of the upper airway structure, impairment in respiratory functions, and hormonal changes (17) (18) (19) (20) . Sleep fragmentation, typically associated with OSA may cause an increase in hunger and appetite (21) . In the present study, the main novel finding was that, despite the tendency to regain some weight from the maximal weight loss immediately after the VLCD, the improvements in OSA achieved by diet-and physical activitybased lifestyle changes in conjunction with the weight loss were sustained, even ameliorated over the 2-y follow-up. This supports the theory of the complex association between excess body weight and OSA and the recent findings that, in patients with OSA, ,50% of the overall response (changes in AHI) to weight loss may be related to reductions in passive mechanical properties and the remaining to concomitant improvements in neuromuscular control of the upper airway (22) . Most importantly, it also supports our belief that a weight-reduction program based on dietary counseling and increased physical activity should be the first-line treatment in the early phases of the disease (ie, mild OSA) when it is associated with overweight. At this stage, it is most likely that the organ systems still possess the ability to recover from the adverse effects of the disease or, at least, that the progression of the disease can be prevented, as was observed in the present study. Our earlier findings and those of another randomized study both showed that weight reduction resulted in a significant relief of partial and complete obstructions by reducing both hypopnea and particularly apnea indexes, which could explain the stability of improvements achieved in respiration during sleep (12, 13) . Moreover, the importance of regular physical activity as part of a lifestyle intervention cannot be overemphasized. Although not shown unequivocally in the present study in our overweight patients (a relatively small sample size), the association between regular exercise and a reduced likelihood of sleep disordered breathing was previously well-characterized (23) .
The current gold standard of OSA treatment is continuous positive airway pressure (CPAP). CPAP treatment may help to control the symptoms, but it must be used every night on a regular basis. However, in mild OSA, compliance with CPAP is frequently unsatisfactory (24) . Furthermore, the possible beneficial effects of CPAP treatment on metabolism are still far from fully proven (25) . A third randomized study in moderate-to-severe OSA patients with CPAP showed that an adjuvant weight-loss SUSTAINED IMPROVEMENTS OF OSA BY LIFESTYLE CHANGES intervention significantly improved OSA compared with CPAP; unfortunately, no metabolic variables other than anthropometric measurements were described in the report (26) . Nonetheless, that study showed that weight-reduction programs do have an important role even for patients with more severe OSA. It has been commonly claimed that a lifestyle change may not be sufficient when treating patients with OSA; however, 3 recent randomized studies have shown that the more aggressive treatment of obesity in OSA patients is well-founded (12, 13, 26) . In the present study, it was noted that the larger the change in body weight, the greater the improvement in OSA. Furthermore, the data from the 3-, 12-, and 24-mo sleep measurements were consistent in strongly favoring the weight-reduction group. It has been suggested that sleep disturbance co-aggregates with other components of the metabolic syndrome and could be its second most important determinant, after obesity (27) . Therefore, it is notable that in the present study, in conjunction with the improvement in OSA, weight reduction was also found to result in improvements in other obesity-related risk factors for cardiovascular diseases.
Recent epidemiologic studies have concluded that OSA is an important risk factor for mortality, particularly because of coronary artery disease, although only in patients with severe disease (AHI . 30 events/h) (7, 28, 29) . This can easily lead one to conclude erroneously that efforts should emphasize the identification and treatment of only patients with severe OSA. However, OSA progresses from mild sleep disordered breathing to more severe OSA over a varying period of time, which may be surprisingly short if it is accompanied by weight gain and a lack of effective treatment (10, 11) . Taking into account the recent findings that OSA increases the risk of cardiovascular mortality and that even mild OSA is associated with the activation of the pro-inflammatory system, we argue that early intervention is indicated to prevent the progression of OSA and the development of other obesity-related complications (7, 8, 28) . Although the risk increases, not all obese persons develop OSA. It can be assumed that weight gain, especially in patients who already have partial obstruction of their upper airways, such as occurs in mild OSA, represents a strong risk factor for further progression of the disease toward its more severe form (11, 30 ). An early intervention in the risk-group individuals (ie, lifestyle changes) has already been shown to be an effective means for prevention of type 2 diabetes in the Finnish Diabetes Prevention Study (DPS) and US Diabetes Prevention Program (DPP), and subsequently large population-based prevention programs have been implemented (31, 32) . A similar approach with relatively simple lifestyle interventions could be applicable also for OSA patients to reduce disease progression and thus prevent increased morbidity and mortality.
The intervention was conducted in patients with mild OSA, and the dietary counseling was provided by a clinical nutritionist who had extensive experience in the treatment of severe obesity. Therefore, the findings may not be directly generalizable to all OSA patients, and compliance with the treatment was fairly high, which may be difficult to achieve in practice. Although these data are encouraging, they need to be replicated in a larger study. Furthermore, because of the relatively small sample sizes, our study was not originally designed to distinguish and compare the effect of the different components of the lifestyle intervention. Although the standard for diagnosing OSA has been based on inlaboratory polysomnography, the cardiorespiratory devices used in the present study may be acceptable for diagnosing and monitoring the response to non-CPAP treatments for OSA, with some limitations (33) .
The treatment of OSA is demanding for both patients and health care personnel because no simple treatment modalities are available. Clarification of the clinical guidelines is clearly needed, as are the identification of novel treatment options for OSA patients and the improvement of the existing treatment modalities. Despite the earlier beliefs that lifestyle intervention programs may not be sufficient or long-lasting when treating patients with OSA, our results show that these arguments may not be fully justified. Our 2-y follow-up showed that the favorable changes achieved by supervised lifestyle intervention are sustained even after the termination of the intervention.
